You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThioridazine
Accession NumberDB00679  (APRD00596)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)
Structure
Thumb
Synonyms
10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine
2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
Mallorol
Malloryl
Meleril
Mellaril
Mellaril-S
Mellerets
Mellerette
Melleril
Orsanil
Sonapax
Thioridazin
Thioridazinum
Tioridazina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mellarilliquid30 mgoralNovartis Pharmaceuticals Canada Inc1997-08-152001-07-30Canada
Mellarilsuspension10 mgoralNovartis Pharmaceuticals Canada Inc1964-12-312001-07-30Canada
Mellaril Tab 100mgtablet100 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 10mgtablet10 mgoralSandoz Canada Inc1959-12-311997-08-12Canada
Mellaril Tab 200mgtablet200 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 25mgtablet25 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 50mgtablet50 mgoralSandoz Canada Inc1959-12-311996-09-23Canada
Novo-ridazine (thioridazine Oral Suspension) - 2 mg/mlsuspension2 mgoralNovopharm Limited1996-09-182005-08-10Canada
Novo-ridazine 100mgtablet100 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 10mgtablet10 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 25mgtablet25 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 50mgtablet50 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine Tab 200mgtablet200 mgoralNovopharm Limited1973-12-312005-08-10Canada
PMS Thioridazine Tab 50mgtablet50 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine 100mg/tab USPtablet100 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine 10mg/tab USPtablet10 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine Solution 30mg/mlsolution30 mgoralPharmascience Inc1988-12-312004-05-24Canada
PMS-thioridazine Solution 5mg/mlsolution5 mgoralPharmascience Inc1988-12-311996-09-09Canada
PMS-thioridazine Tab 25mgtablet25 mgoralPharmascience Inc1984-12-312004-05-24Canada
Thioridazine Oral Sus 2mg/mlsuspension2 mgoralSands Pharm1972-12-311996-09-10Canada
Thioridazine Tab 10mgtablet10 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Thioridazine Tab 25mgtablet25 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Thioridazine Tab 50mgtablet50 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMylan Institutional Inc.1995-06-12Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMylan Institutional Inc.1998-05-06Not applicableUs
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMylan Institutional Inc.1998-06-22Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1998-04-29Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.1983-11-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AldazineNot Available
MallorolNot Available
MelerilNot Available
MelleretteNot Available
MellerettenNot Available
MellerilNot Available
NovoridazineNot Available
RidazinNot Available
RidazineNot Available
SonapaxNot Available
ThiorilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thioridazine Hydrochloride
130-61-0
Thumb
  • InChI Key: NZFNXWQNBYZDAQ-UHFFFAOYNA-N
  • Monoisotopic Mass: 406.130417961
  • Average Mass: 407.035
DBSALT000503
Categories
UNIIN3D6TG58NI
CAS number50-52-2
WeightAverage: 370.575
Monoisotopic: 370.153740222
Chemical FormulaC21H26N2S2
InChI KeyInChIKey=KLBQZWRITKRQQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine
SMILES
CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Alkylarylthioether
  • Benzenoid
  • Piperidine
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of schizophrenia and generalized anxiety disorder.
PharmacodynamicsThioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionThioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
Absorption60%
Volume of distributionNot Available
Protein binding95%
Metabolism

Hepatic

Route of eliminationNot Available
Half life21-25 hours
ClearanceNot Available
ToxicityLD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9068
Blood Brain Barrier+0.9901
Caco-2 permeable+0.7912
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9115
Renal organic cation transporterInhibitor0.7943
CYP450 2C9 substrateNon-substrate0.7981
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5068
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.908
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.7697
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5826
Ames testNon AMES toxic0.8703
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5395 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.906
hERG inhibition (predictor II)Inhibitor0.8384
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Hi tech pharmacal co inc
  • Pharmaceutical assoc inc div beach products
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Ivax pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Liquidoral30 mg
Suspensionoral10 mg
Tabletoral100 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral200 mg
Solutionoral30 mg
Solutionoral5 mg
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Suspensionoral2 mg
Prices
Unit descriptionCostUnit
Thioridazine hcl powder11.16USD g
Thioridazine HCl 200 mg tablet1.14USD tablet
Thioridazine HCl 150 mg tablet1.01USD tablet
Thioridazine HCl 100 mg tablet0.69USD tablet
Thioridazine 100 mg tablet0.67USD tablet
Thioridazine HCl 50 mg tablet0.61USD tablet
Thioridazine 50 mg tablet0.58USD tablet
Thioridazine HCl 25 mg tablet0.49USD tablet
Thioridazine 25 mg tablet0.47USD tablet
Thioridazine HCl 15 mg tablet0.45USD tablet
Thioridazine HCl 10 mg tablet0.35USD tablet
Thioridazine 10 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point73 °CPhysProp
boiling point230 °C at 2.00E-02 mm HgPhysProp
water solubility0.0336 mg/LNot Available
logP5.90HANSCH,C ET AL. (1995)
pKa9.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.000855 mg/mLALOGPS
logP5.93ALOGPS
logP5.47ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity113.52 m3·mol-1ChemAxon
Polarizability43.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.15 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-006t-9552000000-ea4c5c56ee4333d0815aView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (44.7 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Thioridazine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Thioridazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Thioridazine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Thioridazine can be increased when it is combined with Acebutolol.
AcebutololThioridazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Thioridazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Thioridazine.
adipiplonThe risk or severity of adverse effects can be increased when Thioridazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Agomelatine.
AjmalineThe serum concentration of Thioridazine can be increased when it is combined with Ajmaline.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Thioridazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alfaxalone.
AlfentanilThioridazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thioridazine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Thioridazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thioridazine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Thioridazine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Thioridazine.
AlphacetylmethadolThioridazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Thioridazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thioridazine.
AlprenololThioridazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmantadineAmantadine may increase the QTc-prolonging activities of Thioridazine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Thioridazine.
AmiodaroneThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.
AmiodaroneThioridazine may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.
AmitriptylineThe serum concentration of Thioridazine can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amitriptyline.
AmlodipineThe serum concentration of Thioridazine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Thioridazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amperozide.
AmphetamineThe serum concentration of Thioridazine can be increased when it is combined with Amphetamine.
AmphetamineThioridazine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Thioridazine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Thioridazine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Thioridazine.
AntipyrineThe serum concentration of Thioridazine can be increased when it is combined with Antipyrine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Thioridazine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Thioridazine.
AprindineThe metabolism of Aprindine can be decreased when combined with Thioridazine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Thioridazine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Thioridazine.
AripiprazoleThe serum concentration of Thioridazine can be increased when it is combined with Aripiprazole.
AripiprazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aripiprazole.
ArmodafinilThe metabolism of Thioridazine can be decreased when combined with Armodafinil.
ArotinololThioridazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThioridazine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThioridazine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of Thioridazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Articaine.
AsenapineThe serum concentration of Thioridazine can be increased when it is combined with Asenapine.
AsenapineThioridazine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Thioridazine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Thioridazine.
AtenololThioridazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe serum concentration of Thioridazine can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.
AtovaquoneThe serum concentration of Thioridazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Azaperone.
AzelastineThe serum concentration of Thioridazine can be increased when it is combined with Azelastine.
AzelastineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Thioridazine.
BaclofenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Thioridazine.
BefunololThioridazine may increase the hypotensive activities of Befunolol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Thioridazine.
BenzocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benzocaine.
BenzphetamineThioridazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be decreased when combined with Thioridazine.
BetaxololThe serum concentration of Thioridazine can be increased when it is combined with Betaxolol.
BetaxololThioridazine may increase the hypotensive activities of Betaxolol.
BevantololThioridazine may increase the hypotensive activities of Bevantolol.
BezitramideThioridazine may increase the hypotensive activities of Bezitramide.
BicalutamideThe serum concentration of Thioridazine can be increased when it is combined with Bicalutamide.
BiperidenThe serum concentration of Thioridazine can be increased when it is combined with Biperiden.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololThioridazine may increase the hypotensive activities of Bisoprolol.
BopindololThioridazine may increase the hypotensive activities of Bopindolol.
BortezomibThe serum concentration of Thioridazine can be increased when it is combined with Bortezomib.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Thioridazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
BrimonidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thioridazine.
BrompheniramineThe serum concentration of Thioridazine can be increased when it is combined with Brompheniramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brotizolam.
BufuralolThioridazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thioridazine.
BupranololThioridazine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Thioridazine can be increased when it is combined with Buprenorphine.
BuprenorphineThioridazine may increase the hypotensive activities of Buprenorphine.
BupropionThe serum concentration of Thioridazine can be increased when it is combined with Bupropion.
BupropionThe metabolism of Bupropion can be decreased when combined with Thioridazine.
BuserelinBuserelin may increase the QTc-prolonging activities of Thioridazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioridazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thioridazine.
ButacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butethal.
ButorphanolThioridazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thioridazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioridazine.
CaffeineThe metabolism of Thioridazine can be decreased when combined with Caffeine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CaptoprilThe metabolism of Captopril can be decreased when combined with Thioridazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thioridazine.
CarbinoxamineThe serum concentration of Thioridazine can be increased when it is combined with Carbinoxamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carbinoxamine.
CarfentanilThioridazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Thioridazine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Thioridazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carisoprodol.
CarteololThe serum concentration of Thioridazine can be increased when it is combined with Carteolol.
CarteololThioridazine may increase the hypotensive activities of Carteolol.
CarvedilolThioridazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.
CeliprololThioridazine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Thioridazine.
CeritinibCeritinib may increase the QTc-prolonging activities of Thioridazine.
CerivastatinThe serum concentration of Thioridazine can be increased when it is combined with Cerivastatin.
CetirizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Thioridazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Thioridazine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thioridazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Thioridazine can be increased when it is combined with Chloroquine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Thioridazine.
ChlorphenamineThe serum concentration of Thioridazine can be increased when it is combined with Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorphenamine.
ChlorphentermineThioridazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorzoxazone.
CholecalciferolThe serum concentration of Thioridazine can be increased when it is combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Thioridazine.
CimetidineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Thioridazine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thioridazine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Thioridazine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Thioridazine.
CisaprideThe serum concentration of Thioridazine can be increased when it is combined with Cisapride.
CisaprideThioridazine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Thioridazine can be increased when it is combined with Citalopram.
CitalopramThioridazine may increase the QTc-prolonging activities of Citalopram.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Thioridazine.
ClemastineThe serum concentration of Thioridazine can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.
ClidiniumThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clidinium.
ClobazamThe serum concentration of Thioridazine can be increased when it is combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with clomethiazole.
ClomipramineThe serum concentration of Thioridazine can be increased when it is combined with Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thioridazine.
ClotrimazoleThe serum concentration of Thioridazine can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Thioridazine can be increased when it is combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clozapine.
CobicistatThe serum concentration of Thioridazine can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Thioridazine can be increased when it is combined with Cocaine.
CocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cocaine.
CodeineThe serum concentration of Thioridazine can be increased when it is combined with Codeine.
CodeineThioridazine may increase the hypotensive activities of Codeine.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Thioridazine.
CyclizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioridazine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Thioridazine.
CyclosporineThe serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Thioridazine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Thioridazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thioridazine.
DapoxetineDapoxetine may increase the arrhythmogenic activities of Thioridazine.
DapoxetineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dapoxetine.
DapsoneThe serum concentration of Thioridazine can be increased when it is combined with Dapsone.
DarifenacinThe serum concentration of Thioridazine can be increased when it is combined with Darifenacin.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Thioridazine.
DarunavirThe serum concentration of Thioridazine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Thioridazine.
DasatinibDasatinib may increase the QTc-prolonging activities of Thioridazine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Thioridazine.
DeferasiroxThe serum concentration of Thioridazine can be increased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Thioridazine.
DelavirdineThe serum concentration of Thioridazine can be increased when it is combined with Delavirdine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Thioridazine.
deramciclaneThe risk or severity of adverse effects can be increased when Thioridazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desflurane.
DesipramineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desipramine.
DesloratadineThe serum concentration of Thioridazine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.
DetomidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine.
DexfenfluramineThe serum concentration of Thioridazine can be increased when it is combined with Dexfenfluramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Thioridazine.
DexmedetomidineThe serum concentration of Thioridazine can be increased when it is combined with Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexmedetomidine.
DexmethylphenidateThe serum concentration of Thioridazine can be increased when it is combined with Dexmethylphenidate.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Thioridazine.
DextroamphetamineThe serum concentration of Thioridazine can be increased when it is combined with Dextroamphetamine.
DextroamphetamineThioridazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe serum concentration of Thioridazine can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Thioridazine.
DextromoramideThioridazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Thioridazine.
DextropropoxypheneThe serum concentration of Thioridazine can be increased when it is combined with Dextropropoxyphene.
DextropropoxypheneThioridazine may increase the hypotensive activities of Dextropropoxyphene.
DezocineThioridazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Thioridazine.
DiazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Difenoxin.
DihydrocodeineThioridazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thioridazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioridazine.
DihydroetorphineThioridazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thioridazine.
DihydromorphineThioridazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thioridazine.
DiltiazemThe serum concentration of Thioridazine can be increased when it is combined with Diltiazem.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Thioridazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dimenhydrinate.
Dimethyl sulfoxideThe serum concentration of Thioridazine can be increased when it is combined with Dimethyl sulfoxide.
DiphenhydramineThe serum concentration of Thioridazine can be increased when it is combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diphenhydramine.
DiphenoxylateThioridazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thioridazine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Thioridazine.
DofetilideDofetilide may increase the QTc-prolonging activities of Thioridazine.
DolasetronDolasetron may increase the QTc-prolonging activities of Thioridazine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Thioridazine.
DomperidoneThioridazine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Thioridazine.
DopamineThe metabolism of Dopamine can be decreased when combined with Thioridazine.
DoramectinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Doramectin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Thioridazine.
DoxepinThe serum concentration of Thioridazine can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Doxepin.
DoxorubicinThe serum concentration of Thioridazine can be increased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Thioridazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
DoxylamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Doxylamine.
DPDPEThioridazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Thioridazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
DronedaroneThe serum concentration of Thioridazine can be increased when it is combined with Dronedarone.
DronedaroneThioridazine may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Thioridazine.
DroperidolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Drotebanol.
DuloxetineThe serum concentration of Thioridazine can be increased when it is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thioridazine.
EcgonineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thioridazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Thioridazine can be increased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Thioridazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioridazine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Thioridazine.
EliglustatThioridazine may increase the QTc-prolonging activities of Eliglustat.
EncainideThe metabolism of Encainide can be decreased when combined with Thioridazine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Thioridazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thioridazine.
EntacaponeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Entacapone.
EnzalutamideThe serum concentration of Thioridazine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Thioridazine can be increased when it is combined with Epinastine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Thioridazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioridazine.
EribulinEribulin may increase the QTc-prolonging activities of Thioridazine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Thioridazine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Thioridazine.
EscitalopramThe serum concentration of Thioridazine can be increased when it is combined with Escitalopram.
EscitalopramThioridazine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe metabolism of Thioridazine can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Thioridazine.
EsmololThioridazine may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Thioridazine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thioridazine.
EthanolThioridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Thioridazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thioridazine.
EthosuximideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl loflazepate.
EthylmorphineThioridazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thioridazine.
EtidocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thioridazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etoperidone.
EtoricoxibThe serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Thioridazine.
EtorphineThioridazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Thioridazine.
EtravirineThe metabolism of Thioridazine can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Thioridazine.
FelbamateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Felbamate.
FelodipineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fencamfamine.
FenfluramineThe serum concentration of Thioridazine can be increased when it is combined with Fenfluramine.
FenfluramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fenfluramine.
FentanylThioridazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioridazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.
FexofenadineThe serum concentration of Thioridazine can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Thioridazine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Thioridazine.
FlecainideThe serum concentration of Thioridazine can be increased when it is combined with Flecainide.
FlecainideThe metabolism of Flecainide can be decreased when combined with Thioridazine.
FlibanserinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Thioridazine.
FludiazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flunitrazepam.
FluoxetineThe serum concentration of Thioridazine can be increased when it is combined with Fluoxetine.
FluoxetineThioridazine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolThioridazine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Thioridazine can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluticasone Propionate.
FluvastatinThe serum concentration of Thioridazine can be increased when it is combined with Fluvastatin.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Thioridazine.
FluvoxamineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Thioridazine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Thioridazine.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Thioridazine.
FosphenytoinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thioridazine.
GabapentinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thioridazine is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Thioridazine.
GalantamineGalantamine may increase the QTc-prolonging activities of Thioridazine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Thioridazine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Thioridazine can be increased when it is combined with Gefitinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Thioridazine.
GemfibrozilThe metabolism of Thioridazine can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Thioridazine.
GlutethimideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Glutethimide.
GoserelinGoserelin may increase the QTc-prolonging activities of Thioridazine.
GranisetronThe serum concentration of Thioridazine can be increased when it is combined with Granisetron.
GranisetronThe metabolism of Granisetron can be decreased when combined with Thioridazine.
GuanfacineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Halazepam.
HalofantrineThe serum concentration of Thioridazine can be increased when it is combined with Halofantrine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Thioridazine.
HaloperidolThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Halothane.
HeroinThioridazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Thioridazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hexobarbital.
Histamine PhosphateThe serum concentration of Thioridazine can be increased when it is combined with Histamine Phosphate.
HistrelinHistrelin may increase the QTc-prolonging activities of Thioridazine.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Thioridazine resulting in a loss in efficacy.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thioridazine.
HydromorphoneThioridazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thioridazine.
Hydroxyamphetamine hydrobromideThioridazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Thioridazine can be increased when it is combined with Hydroxychloroquine.
HydroxyureaThe serum concentration of Thioridazine can be increased when it is combined with Hydroxyurea.
HydroxyzineThe serum concentration of Thioridazine can be increased when it is combined with Hydroxyzine.
HydroxyzineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Thioridazine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Thioridazine.
IbutilideIbutilide may increase the QTc-prolonging activities of Thioridazine.
IdarubicinThe serum concentration of Thioridazine can be increased when it is combined with Idarubicin.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Thioridazine.
IloperidoneThioridazine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Thioridazine can be increased when it is combined with Imatinib.
ImatinibThe metabolism of Imatinib can be decreased when combined with Thioridazine.
ImipramineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Thioridazine.
IndalpineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Thioridazine.
IndenololThioridazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Thioridazine can be increased when it is combined with Indinavir.
indisulamThe serum concentration of Thioridazine can be increased when it is combined with indisulam.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.
IrbesartanThe serum concentration of Thioridazine can be increased when it is combined with Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioridazine.
IsofluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isoflurane.
IsoniazidThe serum concentration of Thioridazine can be increased when it is combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Thioridazine.
ItraconazoleThe serum concentration of Thioridazine can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Thioridazine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Thioridazine.
KetamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketazolam.
KetobemidoneThioridazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Thioridazine.
KetoconazoleThe serum concentration of Thioridazine can be increased when it is combined with Ketoconazole.
LabetalolThe serum concentration of Thioridazine can be increased when it is combined with Labetalol.
LabetalolThioridazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lamotrigine.
LansoprazoleThe serum concentration of Thioridazine can be increased when it is combined with Lansoprazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Thioridazine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Thioridazine.
LercanidipineThe serum concentration of Thioridazine can be increased when it is combined with Lercanidipine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Thioridazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levetiracetam.
LevobunololThioridazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Thioridazine.
Levomethadyl AcetateThioridazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Thioridazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levomilnacipran.
LevorphanolThioridazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thioridazine.
LidocaineThe serum concentration of Thioridazine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioridazine.
LisdexamfetamineThioridazine may decrease the stimulatory activities of Lisdexamfetamine.
LisurideThe metabolism of Lisuride can be decreased when combined with Thioridazine.
LithiumLithium may increase the neurotoxic activities of Thioridazine.
LithiumThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lithium.
LofentanilThioridazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Thioridazine.
LomustineThe serum concentration of Thioridazine can be increased when it is combined with Lomustine.
LomustineThe metabolism of Lomustine can be decreased when combined with Thioridazine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Thioridazine.
LopinavirThe serum concentration of Thioridazine can be increased when it is combined with Lopinavir.
LopinavirThioridazine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Thioridazine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thioridazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thioridazine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Thioridazine.
LovastatinThe serum concentration of Thioridazine can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thioridazine.
Lu AA21004The risk or severity of adverse effects can be increased when Thioridazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Thioridazine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Thioridazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Thioridazine can be increased when it is combined with Lumefantrine.
LumefantrineThioridazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioridazine.
MeclizineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Medetomidine.
MefloquineThe serum concentration of Thioridazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Thioridazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Melperone.
MephentermineThioridazine may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Thioridazine.
MepivacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.
MepyramineThe serum concentration of Thioridazine can be increased when it is combined with Mepyramine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Thioridazine.
MesoridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.
MethadoneThe serum concentration of Thioridazine can be increased when it is combined with Methadone.
MethadoneThioridazine may increase the hypotensive activities of Methadone.
Methadyl AcetateThioridazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Thioridazine.
MethamphetamineThe serum concentration of Thioridazine can be increased when it is combined with Methamphetamine.
MethamphetamineThioridazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methaqualone.
MethazolamideThe serum concentration of Thioridazine can be increased when it is combined with Methazolamide.
MethimazoleThe serum concentration of Thioridazine can be increased when it is combined with Methimazole.
MethocarbamolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thioridazine.
MethotrimeprazineThe serum concentration of Thioridazine can be increased when it is combined with Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methsuximide.
MethylnaltrexoneThe serum concentration of Thioridazine can be increased when it is combined with Methylnaltrexone.
MethylphenidateThe serum concentration of Thioridazine can be increased when it is combined with Methylphenidate.
MethylphenidateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenobarbital.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Thioridazine.
MetipranololThioridazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe serum concentration of Thioridazine can be increased when it is combined with Metoclopramide.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Thioridazine.
MetoprololThe serum concentration of Thioridazine can be increased when it is combined with Metoprolol.
MetoprololThioridazine may increase the hypotensive activities of Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Thioridazine.
MetyrosineThioridazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thioridazine.
MexiletineThe metabolism of Thioridazine can be decreased when combined with Mexiletine.
MianserinThe serum concentration of Thioridazine can be increased when it is combined with Mianserin.
MianserinThe metabolism of Mianserin can be decreased when combined with Thioridazine.
MibefradilThe serum concentration of Thioridazine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Thioridazine can be increased when it is combined with Miconazole.
MidazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.
MidodrineThe serum concentration of Thioridazine can be increased when it is combined with Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Thioridazine.
MilnacipranThe risk or severity of adverse effects can be increased when Thioridazine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Thioridazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
MirabegronThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Thioridazine.
MirtazapineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe serum concentration of Thioridazine can be increased when it is combined with Mirtazapine.
MoclobemideThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Thioridazine.
ModafinilThe metabolism of Thioridazine can be decreased when combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Thioridazine.
MolindoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Molindone.
MorphineThioridazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thioridazine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Thioridazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
NabiloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nabilone.
NadololThioridazine may increase the hypotensive activities of Nadolol.
NalbuphineThioridazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thioridazine.
NaloxegolThe serum concentration of Thioridazine can be increased when it is combined with Naloxegol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thioridazine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Thioridazine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.
NefazodoneThe serum concentration of Thioridazine can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Thioridazine.
NelfinavirThe serum concentration of Thioridazine can be increased when it is combined with Nelfinavir.
NetupitantThe metabolism of Netupitant can be decreased when combined with Thioridazine.
NevirapineThe serum concentration of Thioridazine can be increased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Thioridazine.
NiacinThe serum concentration of Thioridazine can be increased when it is combined with Niacin.
NicardipineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Thioridazine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Thioridazine.
NicotinamideThe serum concentration of Thioridazine can be increased when it is combined with Nicotinamide.
NicotineThe metabolism of Nicotine can be decreased when combined with Thioridazine.
NifedipineThe serum concentration of Thioridazine can be increased when it is combined with Nifedipine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Thioridazine.
NilotinibThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.
NilotinibThioridazine may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrazepam.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Thioridazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Thioridazine.
NormethadoneThioridazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Thioridazine.
NortriptylineThe serum concentration of Thioridazine can be increased when it is combined with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nortriptyline.
OctreotideOctreotide may increase the QTc-prolonging activities of Thioridazine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Thioridazine.
OlanzapineThe serum concentration of Thioridazine can be increased when it is combined with Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olanzapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Thioridazine.
OlopatadineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine.
OmeprazoleThe serum concentration of Thioridazine can be increased when it is combined with Omeprazole.
OndansetronThe serum concentration of Thioridazine can be increased when it is combined with Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ondansetron.
OpiumThioridazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Thioridazine.
OrphenadrineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thioridazine.
OsanetantThe risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant.
OsimertinibThe serum concentration of Thioridazine can be decreased when it is combined with Osimertinib.
OxamniquineThe serum concentration of Thioridazine can be increased when it is combined with Oxamniquine.
OxazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxazepam.
OxprenololThe serum concentration of Thioridazine can be increased when it is combined with Oxprenolol.
OxprenololThioridazine may increase the hypotensive activities of Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxybuprocaine.
OxybutyninThe serum concentration of Thioridazine can be increased when it is combined with Oxybutynin.
OxycodoneThioridazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thioridazine.
OxymetholoneThe serum concentration of Thioridazine can be increased when it is combined with Oxymetholone.
OxymorphoneThioridazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thioridazine.
OxytocinOxytocin may increase the QTc-prolonging activities of Thioridazine.
PaliperidoneThioridazine may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Thioridazine.
PanobinostatThe serum concentration of Thioridazine can be increased when it is combined with Panobinostat.
PantoprazoleThe metabolism of Thioridazine can be decreased when combined with Pantoprazole.
ParaldehydeThioridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Thioridazine.
ParoxetineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Thioridazine.
PazopanibPazopanib may increase the QTc-prolonging activities of Thioridazine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Thioridazine.
Peginterferon alfa-2bThe serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThioridazine may increase the hypotensive activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Thioridazine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Thioridazine.
PentazocineThioridazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thioridazine.
PerampanelThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Thioridazine.
PergolideThe serum concentration of Thioridazine can be increased when it is combined with Pergolide.
PerhexilineThe serum concentration of Thioridazine can be increased when it is combined with Perhexiline.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Thioridazine.
PerospironeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perospirone.
PerphenazineThe serum concentration of Thioridazine can be increased when it is combined with Perphenazine.
PerphenazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perphenazine.
PethidineThioridazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thioridazine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Thioridazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Thioridazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenoxyethanol.
PhentermineThe serum concentration of Thioridazine can be increased when it is combined with Phentermine.
PhentermineThioridazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenytoin.
PimozideThe serum concentration of Thioridazine can be increased when it is combined with Pimozide.
PindololThe serum concentration of Thioridazine can be increased when it is combined with Pindolol.
PindololThioridazine may increase the hypotensive activities of Pindolol.
PioglitazoneThe serum concentration of Thioridazine can be increased when it is combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Thioridazine.
PipotiazineThe serum concentration of Thioridazine can be increased when it is combined with Pipotiazine.
PipotiazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Thioridazine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Thioridazine.
PractololThioridazine may increase the hypotensive activities of Practolol.
PramipexoleThioridazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pramocaine.
PravastatinThe serum concentration of Thioridazine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam.
PraziquantelThe serum concentration of Thioridazine can be increased when it is combined with Praziquantel.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thioridazine.
PrilocaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prilocaine.
PrimaquineThe serum concentration of Thioridazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Primidone.
ProcainamideThioridazine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioridazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thioridazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Thioridazine.
ProguanilThe serum concentration of Thioridazine can be increased when it is combined with Proguanil.
PromazinePromazine may increase the QTc-prolonging activities of Thioridazine.
PromazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Promazine.
PromethazineThe serum concentration of Thioridazine can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Promethazine.
PropafenoneThe serum concentration of Thioridazine can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Proparacaine.
PropofolThe serum concentration of Thioridazine can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Propoxycaine.
PropranololThe serum concentration of Thioridazine can be increased when it is combined with Propranolol.
PropranololThioridazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioridazine.
PSD502The risk or severity of adverse effects can be increased when Thioridazine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Thioridazine.
PyrimethamineThe serum concentration of Thioridazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quazepam.
QuetiapineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.
QuetiapineThioridazine may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Thioridazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thioridazine.
QuinidineThe serum concentration of Thioridazine can be increased when it is combined with Quinidine.
QuinidineThioridazine may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Thioridazine can be increased when it is combined with Quinine.
QuinineThioridazine may increase the QTc-prolonging activities of Quinine.
RabeprazoleThe serum concentration of Thioridazine can be increased when it is combined with Rabeprazole.
RadicicolThe serum concentration of Thioridazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ramelteon.
RanitidineThe serum concentration of Thioridazine can be increased when it is combined with Ranitidine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Thioridazine.
RanolazineThe serum concentration of Thioridazine can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.
ReboxetineThe serum concentration of Thioridazine can be increased when it is combined with Reboxetine.
RemifentanilThioridazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thioridazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thioridazine.
repinotanThe metabolism of repinotan can be decreased when combined with Thioridazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thioridazine.
RifampicinThe metabolism of Thioridazine can be increased when combined with Rifampicin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Thioridazine.
RisperidoneThe serum concentration of Thioridazine can be increased when it is combined with Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Risperidone.
RitonavirThe serum concentration of Thioridazine can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Thioridazine.
RivastigmineThe serum concentration of Thioridazine can be increased when it is combined with Rivastigmine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thioridazine.
RolapitantThe serum concentration of Thioridazine can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Romifidine.
RopiniroleThioridazine may increase the sedative activities of Ropinirole.
RopiniroleThe serum concentration of Thioridazine can be increased when it is combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thioridazine.
RosiglitazoneThe serum concentration of Thioridazine can be increased when it is combined with Rosiglitazone.
RotigotineThioridazine may increase the sedative activities of Rotigotine.
RotigotineThe serum concentration of Thioridazine can be increased when it is combined with Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thioridazine.
RutinThe serum concentration of Thioridazine can be increased when it is combined with Rutin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thioridazine is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Thioridazine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Thioridazine.
SaquinavirThe serum concentration of Thioridazine can be increased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Thioridazine.
ScopolamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thioridazine.
SelegilineThe serum concentration of Thioridazine can be increased when it is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sertindole.
SertralineThe serum concentration of Thioridazine can be increased when it is combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sevoflurane.
SildenafilThe serum concentration of Thioridazine can be increased when it is combined with Sildenafil.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Thioridazine.
SimeprevirThe metabolism of Thioridazine can be decreased when combined with Simeprevir.
SimvastatinThe serum concentration of Thioridazine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Thioridazine.
SinefunginThe serum concentration of Thioridazine can be increased when it is combined with Sinefungin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Thioridazine.
SorafenibThe serum concentration of Thioridazine can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Thioridazine.
SparteineThe serum concentration of Thioridazine can be increased when it is combined with Sparteine.
SparteineThe metabolism of Sparteine can be decreased when combined with Thioridazine.
StiripentolThe risk or severity of adverse effects can be increased when Thioridazine is combined with Stiripentol.
SufentanilThioridazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thioridazine.
SulfadoxineThe serum concentration of Thioridazine can be increased when it is combined with Sulfadoxine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Thioridazine.
SulfametopyrazineThe serum concentration of Thioridazine can be increased when it is combined with Sulfametopyrazine.
SulfanilamideThe serum concentration of Thioridazine can be increased when it is combined with Sulfanilamide.
SulfaphenazoleThe serum concentration of Thioridazine can be increased when it is combined with Sulfaphenazole.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Thioridazine.
SulpirideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thioridazine.
SunitinibSunitinib may increase the QTc-prolonging activities of Thioridazine.
SuvorexantThe risk or severity of adverse effects can be increased when Thioridazine is combined with Suvorexant.
tafenoquineThe serum concentration of Thioridazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of Thioridazine can be increased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Thioridazine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.
TapentadolThe serum concentration of Thioridazine can be increased when it is combined with Tapentadol.
TapentadolThioridazine may increase the hypotensive activities of Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioridazine.
TegaserodThe serum concentration of Thioridazine can be increased when it is combined with Tegaserod.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Thioridazine.
TelavancinTelavancin may increase the QTc-prolonging activities of Thioridazine.
TelithromycinThe serum concentration of Thioridazine can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thioridazine.
TemsirolimusThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Thioridazine can be decreased when combined with Tenofovir.
TerbinafineThe serum concentration of Thioridazine can be increased when it is combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Thioridazine.
TerfenadineThe serum concentration of Thioridazine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Thioridazine.
TeriflunomideThe serum concentration of Thioridazine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Thioridazine.
TetrabenazineThioridazine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrodotoxin.
ThalidomideThioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thioridazine.
TheophyllineThe metabolism of Thioridazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiopental.
ThiothixeneThe serum concentration of Thioridazine can be increased when it is combined with Thiothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiagabine.
TiclopidineThe serum concentration of Thioridazine can be increased when it is combined with Ticlopidine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Thioridazine.
TiletamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiletamine.
TimololThioridazine may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Thioridazine.
TipranavirThe serum concentration of Thioridazine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Thioridazine.
TizanidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Thioridazine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Thioridazine.
TopiramateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.
ToremifeneToremifene may increase the QTc-prolonging activities of Thioridazine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Thioridazine.
TramadolThe serum concentration of Thioridazine can be increased when it is combined with Tramadol.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Thioridazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Thioridazine.
TriazolamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thioridazine.
TrimethoprimThe serum concentration of Thioridazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioridazine.
TripelennamineThe serum concentration of Thioridazine can be increased when it is combined with Tripelennamine.
TriprolidineThe serum concentration of Thioridazine can be increased when it is combined with Triprolidine.
TriprolidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Thioridazine.
TrospiumThe serum concentration of Thioridazine can be increased when it is combined with Trospium.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Thioridazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thioridazine.
VandetanibThioridazine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Thioridazine.
VemurafenibThe serum concentration of Thioridazine can be increased when it is combined with Vemurafenib.
VemurafenibThioridazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Thioridazine can be increased when it is combined with Venlafaxine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Thioridazine.
VerapamilThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Thioridazine.
VilazodoneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vilazodone.
VinblastineThe serum concentration of Thioridazine can be increased when it is combined with Vinblastine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Thioridazine.
VinorelbineThe serum concentration of Thioridazine can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Thioridazine.
VoriconazoleThe metabolism of Thioridazine can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Thioridazine.
VortioxetineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Xylazine.
YohimbineThe serum concentration of Thioridazine can be increased when it is combined with Yohimbine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Thioridazine.
ZafirlukastThe serum concentration of Thioridazine can be increased when it is combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Thioridazine.
ZaleplonThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zimelidine.
ZiprasidoneThe serum concentration of Thioridazine can be increased when it is combined with Ziprasidone.
ZiprasidoneThioridazine may increase the QTc-prolonging activities of Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioridazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thioridazine.
ZonisamideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zotepine.
ZuclopenthixolThioridazine may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14-20. [PubMed:1978482 ]
  2. Assie MB, Sleight AJ, Koek W: Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol. 1993 Jun 24;237(2-3):183-9. [PubMed:7689973 ]
  3. Dimpfel W, Spuler M, Wessel K: Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology (Berl). 1992;107(2-3):195-202. [PubMed:1352051 ]
  4. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, Phebus LA: Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006 May 22;78(26):3007-12. Epub 2006 Jan 24. [PubMed:16434058 ]
  5. Carey GJ, Bergman J: Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology (Berl). 1997 Aug;132(3):261-9. [PubMed:9292626 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Hammock RG, Schroeder SR, Levine WR: The effect of clozapine on self-injurious behavior. J Autism Dev Disord. 1995 Dec;25(6):611-26. [PubMed:8720030 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  2. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY: Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem. 1986 Jan;46(1):191-7. [PubMed:2866233 ]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773 ]
  3. Burki HR: Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):258-66. [PubMed:2423886 ]
  4. Costall B, Naylor RJ: Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol. 1995 Dec;116(7):2989-99. [PubMed:8680734 ]
  5. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC: Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther. 1999 Feb;288(2):590-6. [PubMed:9918563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC: hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun. 2006 Dec 8;351(1):273-80. Epub 2006 Oct 23. [PubMed:17056009 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23